Analysts Are Bullish on These Healthcare Stocks: CIVI, RARE

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Civitas (NYSE: CIVI) and Ultragenyx (NASDAQ: RARE) with bullish sentiments.

Civitas (NYSE: CIVI)

In a report released yesterday, Richard Close from Canaccord Genuity reiterated a Buy rating on Civitas (NYSE: CIVI), with a price target of $26. The company’s shares opened today at $16.65, close to its 52-week low of $15.19.

According to TipRanks.com, Close is a 2-star analyst with an average return of 0.1% and a 38.5% success rate. Close covers the Technology sector, focusing on stocks such as Castlight Health, Evolent Health, and Athenahealth.

Civitas has an analyst consensus of Moderate Buy.

Ultragenyx (NASDAQ: RARE)

Canaccord Genuity analyst Arlinda Lee reiterated a Buy rating on Ultragenyx (NASDAQ: RARE) yesterday and set a price target of $103. The company’s shares opened today at $79.29.

According to TipRanks.com, Lee is a 1-star analyst with an average return of -2.5% and a 41.9% success rate. Lee covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Actinium Pharmaceuticals, and Asterias Biotherapeutics.

Currently, the analyst consensus on Ultragenyx is Strong Buy and the average price target is $96.50, representing a 21.7% upside.

In a report released yesterday, Piper Jaffray also reiterated a Buy rating on the stock with a $96 price target.